Skip to main content
SpringerLink
Log in

Influence of body mass index and type of low-level exercise on the side effect profile of regadenoson

  • Original Article
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Purpose

Regadenoson, an A2A adenosine receptor pharmacologic stress agent for radionuclide myocardial perfusion imaging (MPI), is administered as a single, fixed dose. We studied the side effect profile of regadenoson combined with two types of low-level exercise, according to body mass index (BMI).

Methods

Three hundred and fifty-six patients (46.1% men, mean age 67.7±10.7 years, range 31–90 years) underwent regadenoson stress testing combined with low-level exercise. Subjects were classified according to BMI as normal, overweight, or obese, and the type of low-level exercise performed as walking on the treadmill (TE group, n=190) or forcefully swinging legs while sitting (SS group, n=166). Patients’ demographics, medical history, clinical symptoms during stress, changes in ECG, oxygen saturation (SatO2), systolic blood pressure (SBP), and heart rate (HR) were evaluated.

Results

Groups were comparable (p=ns) with regard to cardiovascular risks factors. The incidence of side effects was similar across BMI (p=ns), although the TE patients showed improved profiles over those with SS exercise, with a significantly lower incidence of flushing, dizziness and nausea/gastrointestinal discomfort (12.9% vs. 28.4%; 19.9% vs. 33.4%; 11.4% vs. 19.2%, respectively; all p<0.05).

Regarding the hemodynamic response, we did not observe significant changes in SBP and HR after regadenoson administration across BMI categories. Comparing the TE and SS groups, no significant changes were observed in SBP, but there was a higher increase in HR in the TE group (p<0.05).

Conclusions

Regadenoson in combination with low-level exercise is safe and well tolerated over a wide range of BMI, with TE exercise showing a better side effect profile than SS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Media centre. Obesity and overweight. Fact sheet N°311 (updated January 2015). http://www.who.int/mediacentre/factsheets/fs311/en/. Accessed 29 July 2016.

  2. WHO. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. WHO technical report series 894. Geneva: World Health Organization; 2000.

    Google Scholar 

  3. Wilson PW, D’Agostino RB, Sullivan L, et al. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med. 2002;162(16):1867–72.

    Article  PubMed  Google Scholar 

  4. Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, Eckel RH. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association scientific statement on obesity and heart disease from the obesity committee of the council on nutrition, physical activity, and metabolism. Circulation. 2006;113:898–918.

    Article  PubMed  Google Scholar 

  5. Madala MC, Franklin BA, Chen AY, Berman AD, Roe MT, Peterson ED, Ohman EM, Smith SC Jr, Gibler WB, McCullough PA. Obesity and age of first non-st-segment elevation myocardial infarction. J Am Coll Cardiol. 2008;52:979–85.

    Article  PubMed  Google Scholar 

  6. Verbene HJ, Acampa W, Anagnostopoulos C, Ballinger J, Bengel F, De Bondt P, et al. EANM procedural guidelines for radionuclide myocardial perfusion imaging with SPECT and SPECT/CT: 2015 revision. Eur J Nucl Med Mol Imaging. 2015;42:1929–40.

    Article  Google Scholar 

  7. McGeoch RJ, Oldroyd KG. Pharmacological options for inducing maximal hyperemia during studies of coronary physiology. Catherter Cardiovasc Interv. 2008;71:198–204.

    Article  Google Scholar 

  8. Rapiscan: EPAR – Product Information – European Medicines Agency. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001176/WC500097100.pdf

  9. Al Jaroudi W, Iskandrian AE. Regadenoson: a new myocardial stress agent. J Am Coll Cardiol. 2009;54:1123–30.

    Article  CAS  PubMed  Google Scholar 

  10. Iskandrian AE, Bateman T, Belardinelli L, et al. Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: results of the ADVANCE phase 3 multicenter international trial. J Nucl Cardiol. 2007;14:645–58.

    Article  PubMed  Google Scholar 

  11. Jager PL, Buiting M, Mouden M, Oostkijk AH, Timmer J, Knollema S. Regadenoson as a new stress agent in myocardial perfusion imaging. Initial experience in The Netherlands. Rev Esp Med Nucl Imagen Mol. 2014;33:346–51.

    CAS  PubMed  Google Scholar 

  12. Thomas GS, Tammelin BR, Schiffman GL, Marquez R, Rice DL, Milikien D, et al. Safety of regadenoson, a selective adenosine A2A agonist, in patients with chronic obstructive pulmonary disease: a randomized, double-blind, placebo-controlled trial (RegCOPD trial). J Nucl Cardiol. 2008;15:319–28.

    Article  PubMed  Google Scholar 

  13. Leaker BR, O’Connor B, Hansel TT, Barnes PJ, Meng L, Mathur VS, Lieu HD. Safety of regadenoson, an adenosine A2A receptor agonist for myocardial perfusion imaging, in mild asthma and moderate asthma patients: a randomized, double-blind, placebo-controlled trial. J Nucl Cardiol. 2008;15:329–36.

    Article  PubMed  Google Scholar 

  14. Prenner BM, Bukofzer S, Behm S, Feaheny K, McNutt BE. A randomized, double-blind, placebo-controlled study assessing the safety and tolerability of regadenoson in subjects with asthma or chronic obstructive pulmonary disease. J Nucl Cardiol. 2012;19:681–92.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Salgado-Garcia C, Jimenez-Heffernan A, Sanchez de Mora E, Ramos-Font C, Lopez-Martin J, Rivera de los Santos F, Ynfante-Mila I. Comparative study of the safety of regadenoson between patients with mild/moderate chronic obstructive pulmonary disease and asthma. Eur J Nucl Med Mol Imaging. 2014;41:119–25.

  16. Golzar Y, Doukky R. Regadenoson use in patients with chronic obstructive pulmonary disease: the state of current knowledge. Int J Chron Obstruct Pulmon Dis. 2014;9:129–37.

    CAS  PubMed  PubMed Central  Google Scholar 

  17. Salgado-Garcia C, Jimenez-Heffernan A, Ramos-Font C, Lopez-Martin J, Sanchez de Mora E, Aroui T, Lopez-Aguilar R, Rivera de los Santos F, Ruiz-Frutos C. Safety of regadenoson in patients with severe chronic obstructive pulmonary disease. Rev Esp Med Nucl Imagen Mol. 2016;35:283–6.

  18. Stratmann HG, Mark AL, Williams GA. Thallium-201 perfusion imaging with atrial pacing or dypiridamole stress testing for evaluation of cardiac risk prior to nonvascular surgery. Clin Cardiol. 1990;13:611–6.

    Article  CAS  PubMed  Google Scholar 

  19. Thomas GS, Prill NV, Majmundar H, Fabrizi RR, Thomas JJ, Hayasida C, et al. Treadmill exercise during adenosine infusion is safe, results in fewer adverse reactions, and improves myocardial perfusion image quality. J Nucl Cardiol. 2000;7(5):439–46.

    Article  CAS  PubMed  Google Scholar 

  20. Kwon DH, Cerqueira MD, Young R, Houghtaling P, Lieber E, Menon V, et al. Lessons from regadenoson and low-level tredmill/regadenoson myocardial perfusion imaging: initial clinical experience in 1263 patients. J Nucl Cardiol. 2010;17(5):853–7.

    Article  PubMed  Google Scholar 

  21. Thomas GS, Thompson RC, Miyamoto MI, et al. The RegEx trial: a randomized, double-blind, placebo- and active-controlled pilot study combining regadenoson, a selective A2A adenosine agonist, with low-level exercise, in patients undergoing myocardial perfusion imaging. J Nucl Cardiol. 2009;16(1):63–72.

    Article  PubMed  Google Scholar 

  22. Elliot MD, Holly TA, Leonard SM, Hendel RC. Impact of an abbreviated adenosine protocol incorporating adjunctive treadmill exercise on adverse effects and image quality in patients undergoing stress myocardial perfusion imaging. J Nucl Cardiol. 2000;7(6):584–9.

    Article  Google Scholar 

  23. Janvier L, Pinaquy J, Douard H, Karcher G, Bordenave L. A useful and easy to develop combined stress test for myocardial perfusion imaging: Regadenoson and isometric exercise, preliminary results. J Nucl Cardiol. 2017;24(1):34–40.

    Article  PubMed  Google Scholar 

  24. Reyes E, Staerh P, Olmsted A, et al. Effect of body mass index on the efficacy, side effect profile, and plasma concentration of fixed-dose regadenoson for myocardial perfusion imaging. J Nucl Cardiol. 2011;18(4):620–7.

    Article  PubMed  Google Scholar 

  25. Mahmarian JJ, Peterson LE, Xu J, Cerqueira MD, et al. Regadenoson provides perfusion results comparable to adenosine in heterogeneous patient population: a quantitative analysis from de ADVANCE MPI trials. J Nucl Cardiol. 2015;22(2):248–61.

    Article  PubMed  Google Scholar 

  26. Salgado C, Jimenez-Heffernan A, Ramos-Font C, Lopez-Martin J, Sanchez de Mora E, Lopez-Aguilar R, et al. Comparison of adverse events between regadenoson and adenosine both combined with low-level exercise in patients with obesity. Eur Heart J Cardiovasc Imaging. 2015;16(suppl 1):i38–55.

    Article  Google Scholar 

  27. Henzlova MJ, Duvall WL, Einstein AJ, Travin MI, Verbene HJ. ASNC imaging guidelines for SPECT nuclear cardiology procedures: stress, protocols, and tracers. J Nucl Cardiol. 2016;23:606–39.

    Article  PubMed  Google Scholar 

  28. Cerqueira MD, Nguyen P, Staehr P, Underwood SR, Iskandrian AE. Effects of age, gender, obesity, and diabetes on the efficacy and safety of the selective A2A agonist regadenoson versus adenosine in myocardial perfusion imaging integrated ADVANCE-MPI trial results. JACC Cardiovasc Imaging. 2008;1:307–16.

    Article  PubMed  Google Scholar 

  29. Gordi T, Frohna P, Hai-Ling S, Wolff A, Belardinelli L, Lieu H. A population pharmacokinetic/pharmacodynamic analysis of regadenoson, an adenosine A2A-receptor agonist, in healthy male volunteers. Clin Pharmacokinet. 2006;45(12):1201–12.

    Article  CAS  PubMed  Google Scholar 

  30. Clarke B, Conradson TB, Dixon CM, et al. Reproducibility of heart rate changes following adenosine infusion in man. Eur J Clin Pharmacol. 1988;35:309–11.

    Article  CAS  PubMed  Google Scholar 

  31. Mahmarian JJ, Cerqueira MD, Iskandrian AE, et al. Regadenoson induces comparable left ventricular perfusion defects as adenosine: a quantitative analysis from the ADVANCE MPI 2 trial. JACC Cardiovasc Imaging. 2009;2:959–68.

    Article  PubMed  Google Scholar 

  32. Dhalla AK, Wong MY, Wang WQ, Biaggioni I, Belardinelli L. Tachycardia caused by A2A adenosine receptor agonist is mediated by direct sympathoexcitation in awake rats. J Pharmacol Exp Ther. 2006;316:695–702.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, Hospital Juan Ramon Jimenez. Complejo Hospitalario Universitario de Huelva, Ronda Norte, s/n, 21005, Huelva, Spain

    Carlos Salgado-Garcia, Amelia Jimenez-Heffernan, Juana Lopez-Martin, Manuela Molina-Mora, Tarik Aroui, Elena Sanchez de Mora & Carlos Ramos-Font

  2. Area of Methodology of Behavioural Sciences, University of Seville, 41018, Seville, Spain

    Francisco Rivera de los Santos

  3. Department of Environmental and Public Health, University of Huelva, 21071, Huelva, Spain

    Carlos Ruiz-Frutos

Authors
  1. Carlos Salgado-Garcia
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Amelia Jimenez-Heffernan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Juana Lopez-Martin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Manuela Molina-Mora
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tarik Aroui
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Elena Sanchez de Mora
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Carlos Ramos-Font
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Francisco Rivera de los Santos
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Carlos Ruiz-Frutos
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carlos Salgado-Garcia.

Ethics declarations

Funding

This research received no grant from any funding agency in the public, commercial or not-for-profit sectors.

Disclosures

The authors declare that there is no conflict of interest.

Ethical approval

All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Salgado-Garcia, C., Jimenez-Heffernan, A., Lopez-Martin, J. et al. Influence of body mass index and type of low-level exercise on the side effect profile of regadenoson. Eur J Nucl Med Mol Imaging 44, 1906–1914 (2017). https://doi.org/10.1007/s00259-017-3717-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-017-3717-1

Keywords

Search

Navigation